Fianlimab, a human lymphocyte activation gene‐3 monoclonal antibody, in combination with cemiplimab: Tumor‐specific expansion cohorts in advanced malignancies

Q: What does this research mean for the field?

The combination of fianlimab and cemiplimab provides modest clinical efficacy and an acceptable safety profile across several tumor types in patients with advanced malignancies. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Tae Min Kim; Stephen K. Williamson; Kyriakos P. Papadopoulos; O Hamid; Grace K. Dy; Ray McDermott; Ariel Birnbaum; John M. Kaczmar; Nehal Lakhani; D Rischin; Debashis Sarker; Afshin Dowlati; Xin‐Hua Zhu; Jyoti Malhotra; Jean‐Francois Pouliot; Jayakumar Mani; Laura Brennan; Fang Fang; Shuquan Chen; Mark Salvati; Israel Lowy; Ahmed Khaled; Karl D. Lewis; Glenn Kroog; Matthew G. Fury; B Cho

doi:10.1002/cncr.70396

Key Points

The study aims to evaluate the clinical efficacy and safety of Fianlimab combined with Cemiplimab in patients with advanced malignancies.
Evaluated patients with advanced malignancies; treatment-naive population.
Combined therapy of Fianlimab and Cemiplimab was administered.
Monitored safety profile and clinical outcomes.
Combination therapy showed modest clinical efficacy across several tumor types.
An acceptable safety profile was observed in treatment-naive patients.
Further investigation is warranted to confirm findings.

Implication

Assesses clinical efficacy of Fianlimab with Cemiplimab in treating advanced malignancies, suggesting further research is needed.

Abstract

Fianlimab plus cemiplimab demonstrated modest clinical efficacy with an acceptable safety profile in patients with advanced malignancies across several tumor types mostly in treatment-naive patients. Further investigation is warranted.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kim et al. (2026) studied this question.

synapsesocial.com/papers/69edae394a46254e215b57ca https://doi.org/10.1002/cncr.70396

View Full Paper

Ask AI

Bookmark

Share

Fianlimab, a human lymphocyte activation gene‐3 monoclonal antibody, in combination with cemiplimab: Tumor‐specific expansion cohorts in advanced malignancies

Key Points

Implication

Abstract

Discussion

Cite This Study

Fianlimab, a human lymphocyte activation gene‐3 monoclonal antibody, in combination with cemiplimab: Tumor‐specific expansion cohorts in advanced malignancies

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading